hotspot -WSS

hotspot

author：leisure time 2025-08-20 09:42:22 - browse：8875

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： New menopause drug shows promise in relief for hot flashes

hotspot

WSS

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Roche acquires Telavant from Roivant, adding experimental IBD treatment

New Medicare drug pricing powers could soon be upended in court

Is there really a nursing shortage in the U.S.?

Caregivers of transplant patients call for more support, training

STAT Summit: The economic case for universal basic health care

focus

hotspot

leisure time

How to save PrEP access — and even expand it

Study on Amgen’s bispecific immunotherapy produces positive data

Tori Bowie and the unacceptable rates of Black maternal death

ADCs take center stage as promising cancer treatments

In age of alternative facts, a scholarly course on calling out crap

Generative AI mines health records to identify patients’ social needs

Continuity nursing helped my family in our darkest PICU moments

New Medicare drug pricing powers could soon be upended in court

Alkermes shareholders re

The SUPPORT Act is critical to fighting the opioid crisis

explore

STAT Summit: Meghan O’Rourke on making chronic illness visible

Why a market frenzy over new weight loss drugs defies logic

Designating disabled people as health disparity population is crucial

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

STAT Summit: How researchers deal with rejection

Roche acquires Telavant from Roivant, adding experimental IBD treatment

knowledge

Wikipedia

hotspot

hotspot